Clinical trials: Nonalcoholic Fatty Liver
NAFLD, Non-alcoholic Fatty Liver Disease
Manual Therapy in Metabolic Liver Disease
Hepatic steatosis is a disease that is becoming more common in our society; approximately 40% of the population suffers from non-alcoholic fatty liver.
- Trial name
- OSTEO-EHMet (NCT06338618)
- Testing
- liver treatment protocol
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- University of Seville
Fatty Liver Disease, Fatty Liver
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD
- Trial name
- MAFLD (NCT05966025)
- Testing
- Itopride, conventional therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- October 6 University
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Alcohol-related Liver Disease, Cirrhosis, Liver
- Trial name
- CHALNA2 (NCT05623150)
- Testing
- Liver biopsy
- Where
- France
- Volunteers
- 710 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Nonalcoholic Fatty Liver Disease, Liver Steatosis
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis
Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China.
- Conditions
- Nonalcoholic Fatty Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT03386890
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）
This is a prospective, multicenter, open-label, non-randomized controlled real-world study to explore the efficacy and safety and to accumulate more evidence-based medical data of an antiviral treatment programme for chronic…
- Trial name
- NCT06368882
- Testing
- Peg-Interferon α
- Where
- 5 sites in China
- Volunteers
- 1,500 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Liver Steatoses, Liver Metastasis Colon Cancer
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
Non-alcoholic fatty liver disease is becoming increasingly common in Canada and throughout the world. Fatty liver can increase the risks of perioperative complications for those who need liver surgery.
- Conditions
- Liver Steatoses, Liver Metastasis Colon Cancer, NAFLD
- Trial name
- NCT05884723
- Testing
- Ketogenic Diet
- Where
- Canada
- Volunteers
- 124 people
- Sponsor
- Anton Skaro
Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)
Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET
This observational study aims to quantify whole-body amino acid and glucose metabolism in healthy adults and in patients with non-alcoholic fatty liver disease (NAFLD) using total-body PET/CT.
- Trial name
- NCT07366710
- Testing
- 18F-FDG (oral), 18F-FDG (intravenous), 18F-FET (oral)
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Non Alcoholic Steatohepatitis
The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
To study the effects of Hesperidin supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI)…
- Trial name
- NCT03377140
- Testing
- Hesperidin, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver disease, and it is increasingly diagnosed in many developed and developing countries.
- Trial name
- NCT05474560
- Testing
- Allopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Non-Alcoholic Fatty Liver Disease, Insulin Resistance
Effects of Carnitine Supplementation on Liver and Muscle
It will be evaluated whether carnitine, a dietary supplement, reduces liver fat and improves metabolism in individuals who have a high concentration of fat within their liver.
- Trial name
- ECLIPSE (NCT03439917)
- Testing
- L-Carnitine tartrate, Meal Replacement Drink, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Nottingham
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be…
- Trial name
- FLiPP (NCT02754037)
- Testing
- Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), PET Explorer
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Davis
Non-Alcoholic Steatohepatitis (NASH)
To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .
A double-blind placebo controlled, randomized, Phase 2b study to evaluate the efficacy and safety of once-daily, oral administration of 80 or 160 mg HSK31679 versus matching placebo in Patients With Non-Alcoholic Steatohepatitis…
- Trial name
- NCT06168383
- Testing
- HSK31679 80mg, HSK31679 160mg
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Nonalcoholic Fatty Liver Disease
Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Endoscopic weight loss procedures, also termed endoscopic sleeve gastroplasty (ESG), has been proposed as a non-surgical procedure for managing obesity and offers a standard weight loss approach.
- Trial name
- NCT05507151
- Testing
- Endoscopic Sleeve Gastroplasty
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- West Virginia University
Coronary Artery Calcification
Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification
Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death.
- Trial name
- NCT01158066
- Testing
- CT Cardiac
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Ziv Hospital
Insulin Resistance, Type2 Diabetes Mellitus
High-fat Overfeeding, Hepatokines and Appetite Regulation
The present study will investigate the effect of high-fat overfeeding on a group of liver-secreted proteins linked to worsened blood sugar control, as well as proteins involved in appetite control.
- Conditions
- Insulin Resistance, Type2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity
- Trial name
- OVEREAT (NCT03369145)
- Testing
- High-fat diet
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Fatty Liver Disease
The Role of Sugars in Fat Accumulation in the Liver
This interventional study has 2 parts. In the part A of the project, we will determine how the acute changes in hepatic fat content (HFC) after high-fat load (150 g of fat) are affected by co-administration with three doses of…
- Trial name
- FROGLOSA (NCT06751862)
- Testing
- 150g of fat with glucose, 150g of fat with fructose, 150g of fat with sucrose
- Where
- Czechia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institute for Clinical and Experimental Medicine
Overweight, Microbiota
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
It has been suggested that the actual obesity epidemy is related to chronic overconsumption of added or free sugars. The increasing popularity of artificial sweeteners attest the population willingness to reduce added sugars…
- Conditions
- Overweight, Microbiota, Endotoxemia, Metabolic Syndrome
- Trial name
- NCT04117802
- Testing
- Maple syrup
- Where
- Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Laval University
Liver Fibrosis Due to NASH
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT01672879)
- Testing
- SIM
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 259 people
- Sponsor
- Gilead Sciences
NAFLD, Metabolic Syndrome
Dietary Supplementation With Butyrate in Individuals With Liver Steatosis and Metabolic Syndrome
This was a double-blind, randomized, placebo-controlled clinical study aiming to assess the effect of a food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3 on liver…
- Trial name
- NCT06398522
- Testing
- Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Bologna
Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease
Potential subjects with non-alcoholic fatty liver disease (NAFLD) will be identified by gastroenterologists (study investigators).
- Trial name
- NCT04371653
- Testing
- PRIM-DJ2727
- Sponsor
- The University of Texas Health Science Center, Houston
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.